계명대학교 의학도서관 Repository

Clinical features and treatment outcomes in patients with mantle cell lymphoma in Korea: Study by the Consortium for Improving Survival of Lymphoma

Metadata Downloads
Author(s)
Byung Woog KangSang Kyun SohnJoon Ho MoonYee Soo ChaeJong Gwang KimSoo Jung LeeWon Seog KimJe-Jung LeeSe Ryeon LeeKeon Uk ParkHo Sup LeeWon Sik LeeJong-Ho WonMoo-Rim ParkJae-Yong KwakMin Kyoung KimHyo Jung KimSung Yong OhHye Jin KangCheolwon Suh
Keimyung Author(s)
Park, Keon Uk
Department
Dept. of Internal Medicine (내과학)
Journal Title
Blood Research
Issued Date
2014
Volume
49
Issue
1
Keyword
Mantle cell lymphomaEpidemiologyTrendSurvivalChemotherapyRituximab
Abstract
Background
We investigated the clinical features and treatment outcomes of patients with mantle cell lymphoma (MCL) in Korea.
Methods
We retrospectively analyzed the clinical characteristics and prognosis of 131 patients di-agnosed with MCL between January 2004 and December 2009 at 15 medical centers in Korea; all patients received at least 1 chemotherapeutic regimen for MCL.
Results
The median age for the patients was 63 years (range, 26‒78 years), and 77.9% were men. A total of 105 patients (80.1%) had stage III or IV MCL at diagnosis. Fifty-two patients (39.7%) were categorized with high- or high-intermediate risk MCL according to the International Prognostic Index (IPI). Eighteen patients (13.7%) were in the high-risk group according to the simplified MCL-IPI (MIPI). The overall incidence of extranodal involve-ment was 69.5%. The overall incidence of bone marrow and gastrointestinal involvements at diagnosis was 41.2% and 35.1%, respectively. Cyclophosphamide, doxorubicin, vin-cristine, prednisolone, and rituximab were used frequently as the first-line treatment (41.2%). With a median follow-up duration of 20.0 months (range, 0.2‒77.0 months), the overall survival (OS) at 2 years was 64.7%, while the event-free survival (EFS) was 39.7%. Multivariate analysis showed that the simplified MIPI was significantly associated with OS. However, the use of a rituximab-containing regimen was not associated with OS and EFS.
Conclusion
Similar to results from Western countries, the current study found that simplified MIPI was an important prognostic factor in Korean patients with MCL.
Keimyung Author(s)(Kor)
박건욱
Publisher
School of Medicine
Citation
Byung Woog Kang et al. (2014). Clinical features and treatment outcomes in patients with mantle cell lymphoma in Korea: Study by the Consortium for Improving Survival of Lymphoma. Blood Research, 49(1), 15–21. doi: 10.5045/br.2014.49.1.15
Type
Article
ISSN
2287-979x
DOI
10.5045/br.2014.49.1.15
URI
https://kumel.medlib.dsmc.or.kr/handle/2015.oak/39963
Appears in Collections:
1. School of Medicine (의과대학) > Dept. of Internal Medicine (내과학)
공개 및 라이선스
  • 공개 구분공개
파일 목록

Items in Repository are protected by copyright, with all rights reserved, unless otherwise indicated.